disappointing preliminary results for a phase three trial of a lung cancer treatment.
AstraZeneca said it slowed progression of the cancer, but the data for overall survival was "not mature" and the results were not statistically significant. The trial will continue to assess overall survival with greater maturity, the company said.
Colombia Últimas Noticias, Colombia Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Nio, XPeng stocks surge after EV delivery dataShares of China-based electric-vehicle makers surged Monday, after they reported June deliveries that showed big jumps from May.
Leer más »
Stocks making the biggest moves in the premarket: Tesla, Apple, AstraZeneca and moreThese are the stocks posting the largest moves in premarket trading.
Leer más »